logo-loader
viewOrgenesis

Orgenesis showcases publication of diabetes study in Stem Cell Research and Therapy Journal

The developer of advanced cell therapies points out that insulin-dependent diabetes is a disorder that could, in theory, be cured by functional pancreatic islets and the implantation of autologous insulin-producing cells

diabetes logo
Orgenesis is a biotech company focused on cell and gene therapies

Orgenesis Inc (NASDAQ:ORGS), a developer of advanced cell therapies, on Wednesday announced the publication of a promising diabetes study entitled “The Role of The Vasculature Niche on Insulin Producing Cells Generated by Transdifferentiation of Adult Human Liver Cells” in the February issue of the Journal of Stem Cell Research and Therapy.

Orgenesis points out that insulin-dependent diabetes is a disorder that could, in theory, be cured by functional pancreatic islets and the implantation of autologous insulin-producing cells.

Results of the study, which focused on insulin-dependent diabetes and was carried out in mice, show that the co-implantation of mesenchymal stem cells (MSCs) and endothelial colony forming cells (ECFCs) with autologous insulin-producing cells led to the doubling of survival rates and a three-fold increase in insulin production.

READ: Orgenesis stock climbs after it posts 139% expansion in gross profit for fiscal 2018 on revenue surge

In a statement, Professor Sarah Ferber, chief scientific officer of Orgenesis, praised the study for offering proof that the transdifferentiation process, which is the conversion of one adult tissue or cell into another type of cell, works.

“In this study, we were able to uncover that vasculature is an important factor in generating regenerative properties and is a fitting approach for the treatment of diabetes,” explained Ferber. “Vasculature enacts cell-to-cell communication, inducing a change of the maturation of insulin producing cells and their survival upon implementation.”

Orgenesis is a biotech company focused on cell and gene therapies.

The Germantown, Maryland-based company’s goal is to utilize its know-how and intellectual property to advance new autologous cell therapies to a clinical stage and enable point-of-care cell therapy development and services.

Two of the most common types of stem cell transplants are autologous and allogeneic transplants. Both kinds of stem cell transplantations are a common treatment option for cancers such as leukemia, lymphoma, and multiple myeloma.

An autologous transplant uses a person's own stem cells, while an allogeneic transplant uses stem cells from a donor whose human leukocyte antigens (HLA) are acceptable matches to the patient’s.

Orgenesis shares held steady at $5.20 in morning trade on Wednesday

Contact Ellen at [email protected]

 

Quick facts: Orgenesis

Price: 3.59 USD

NASDAQ:ORGS
Market: NASDAQ
Market Cap: $60.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orgenesis gets Orphan Drug designation to treat severe diabetes

Orgenesis Inc (NASDAQ:ORGS) Chief Scientific Officer Dr. Sarah Ferber tells Proactive Investors the FDA has granted Orphan Drug designation to its Autologous Insulin Producing (AIP) cells as a cell-replacement therapy for the treatment of severe diabetes following a pancreatectomy, a surgical...

on 06/28/2019

2 min read